



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Makoto TAKETO et al. : **Mail Stop: PCT**  
Serial No. 10/591,817 : Attorney Docket No. 2006\_1487A  
Filed September 6, 2006 :

PHARMACEUTICAL COMPOSITION COMPRISING  
CXCR3 INHIBITOR  
[Corresponding to PCT/JP2005/004098  
Filed March 9, 2005]

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☒ each U.S. Patent and U.S. Patent application publication;
- ☐ each reference previously cited in the international application PCT/\_\_\_\_\_; and/or
- ☐ each reference previously cited in prior parent application Serial No. \_\_\_\_\_.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

**and thus no certification and/or fee is required.**

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and**

**the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified


a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or

b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
  - b. ☐ a foreign patent office search report (in the English language) submitted herewith,
  - c. ☐ the concise explanation contained in the specification of the present application at page,
  - d. ☐ the concise explanation set forth in the attached English language abstract,
  - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☐ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Makoto TAKETO et al.

By   
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
November 27, 2006

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: November 27, 2006

ATTY DOCKET NO.  
2006\_1487ASERIAL NO.  
10/591,817APPLICANT  
Makoto TAKETO et al.FILING DATE  
September 6, 2006

GROUP



## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AB	01/38352	5/2001	WO			Corresponds to JP 2003-516324
	AC	98/11218	3/1998	WO			Corresponds to JP 2002-513388
	AD						
	AE						
	AF						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AG	M. M. Robledo et al., "Expression of Functional Chemokine Receptors CXCR3 and CXCR4 on Human Melanoma Cells", The Journal of Biological Chemistry, Vol. 276, No. 48, pp. 45098-45105, November 30, 2001.
	AH	A. Muller et al., "Involvement of Chemokine Receptors in Breast Cancer Metastasis", Nature, Vol. 410, pp. 50-56, March 1, 2001.
	AI	H. E. Wiley et al., "Expression of CC Chemokine Receptor-7 and Regional Lymph Node Metastasis of B16 Murine Melanoma", Journal of the National Cancer Institute, Vol. 93, No. 21, pp. 1638-1643, November 7, 2001.
	AJ	C. J. Scotton et al., "Epithelial Cancer Cell Migration: A Role for Chemokine Receptors?", Cancer Research, Vol. 61, pp. 4961-4965, July 1, 2001.
	AK	L. Trentin et al., "The Chemokine Receptor CXCR3 is expressed on Malignant B Cells and Mediates Chemotaxis", The Journal of Clinical Investigation, Vol. 104, No. 1, pp. 115-121, July 1999.
	AL	C. S. Tannenbaum et al., "The CXC Chemokines IP-10 and Mig are Necessary for IL-12-Mediated Regression of the Mouse RENCA Tumor", The Journal of Immunology, Vol. 161, pp. 927-932, 1998.
	AM	J. Michael Ruehlmann et al., "MIG (CXCL9) Chemokine Gene Therapy Combines with Antibody-Cytokine Fusion Protein to Suppress Growth and Dissemination of Murine Colon Carcinoma", Cancer Research, Vol. 61, pp. 8498-8503, December 1, 2001.
	AN	C. Sgadari et al., "Mig, the Monokine Induced by Interferon- $\gamma$ , Promotes Tumor Necrosis <i>In Vivo</i> ", Blood, Vol. 89, No. 8, pp. 2635-2643, April 15, 1997.

EXAMINER

DATE CONSIDERED